MS and Demyelinating Disorders

Guest editor-in-chief Darin T. Okuda, MD, FAAN, FANA, details the fast moving field of multiple sclerosis and the direction the disease is moving towards in 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

“Is more always better?”: The age-old question is more relevant than ever as clinicians and patients alike navigate an increasingly crowded MS treatment landscape.

Stephen Krieger, MD from the Icahn School of Medicine at Mount Sinai spoke about the phase 3 trial of nabiximols he will be investigating in MS.

Effectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.

As the adoption of telemedicine rises, the ability to incorporate digital and telehealth-based therapies offers clinicians a unique opportunity to supplement the comprehensive care model.

Advanced imaging technology collides with artificial intelligence in what is shaping up to be a revolutionary period for the diagnosis and management of MS.

Researchers from the Mayo Clinic found a molecular target that can help assess potential treatments for spinocerebellar ataxia type 3, a disease which currently has no cure.

Here's what is coming soon to NeurologyLive.